-
1
-
-
84870946642
-
Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
-
Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013; 34(1): 1-14.
-
(2013)
Infect Control Hosp Epidemiol
, vol.34
, Issue.1
, pp. 1-14
-
-
Sievert, D.M.1
Ricks, P.2
Edwards, J.R.3
-
2
-
-
84886260592
-
Report reveals scope of US antibiotic resistance threat
-
Hampton T. Report reveals scope of US antibiotic resistance threat. JAMA. 2013; 310(16): 1661-1663.
-
(2013)
JAMA
, vol.310
, Issue.16
, pp. 1661-1663
-
-
Hampton, T.1
-
3
-
-
84881139580
-
Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009
-
Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013; 34(9): 940-946.
-
(2013)
Infect Control Hosp Epidemiol
, vol.34
, Issue.9
, pp. 940-946
-
-
Zilberberg, M.D.1
Shorr, A.F.2
-
4
-
-
85027920728
-
Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010
-
Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis. 2013; 76(3): 379-381.
-
(2013)
Diagn Microbiol Infect Dis
, vol.76
, Issue.3
, pp. 379-381
-
-
Babinchak, T.1
Badal, R.2
Hoban, D.3
-
5
-
-
0035038698
-
A practical guide to antimicrobial management of complicated urinary tract infection
-
Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging. 2001; 18(4): 243-254.
-
(2001)
Drugs Aging
, vol.18
, Issue.4
, pp. 243-254
-
-
Nicolle, L.E.1
-
6
-
-
77957708554
-
Complicated urinary tract infections: Practical solutions for the treatment of multiresistant Gram-negative bacteria
-
Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010; 65(suppl 3): iii25-iii33.
-
(2010)
J Antimicrob Chemother
, vol.65
, pp. iii25-iii33
-
-
Pallett, A.1
Hand, K.2
-
7
-
-
84929606496
-
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI)
-
Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015; 385(9981): 1949-1956.
-
(2015)
Lancet
, vol.385
, Issue.9981
, pp. 1949-1956
-
-
Wagenlehner, F.M.1
Umeh, O.2
Steenbergen, J.3
Yuan, G.4
Darouiche, R.O.5
-
8
-
-
73649114948
-
Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
-
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(2): 133-164.
-
(2010)
Clin Infect Dis
, vol.50
, Issue.2
, pp. 133-164
-
-
Solomkin, J.S.1
Mazuski, J.E.2
Bradley, J.S.3
-
9
-
-
84929206762
-
Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
-
Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015; 60(10): 1462-1471.
-
(2015)
Clin Infect Dis
, vol.60
, Issue.10
, pp. 1462-1471
-
-
Solomkin, J.1
Hershberger, E.2
Miller, B.3
-
10
-
-
84919629764
-
Beta-lactam/beta-lactamase inhibitor combinations: From then to now
-
Toussaint KA, Gallagher JC. Beta-lactam/beta-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015; 49(1): 86-98.
-
(2015)
Ann Pharmacother
, vol.49
, Issue.1
, pp. 86-98
-
-
Toussaint, K.A.1
Gallagher, J.C.2
-
11
-
-
77149165713
-
Updated functional classification of beta-lactamases
-
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010; 54(3): 969-976.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.3
, pp. 969-976
-
-
Bush, K.1
Jacoby, G.A.2
-
12
-
-
84940449628
-
Ceftolozane/tazobactam and ceftazidime/avibactam: Two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
-
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015; 46(3): 266-271.
-
(2015)
Int J Antimicrob Agents
, vol.46
, Issue.3
, pp. 266-271
-
-
Liscio, J.L.1
Mahoney, M.V.2
Hirsch, E.B.3
-
13
-
-
77149179342
-
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients
-
Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010; 54(3): 1213-1217.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.3
, pp. 1213-1217
-
-
Moya, B.1
Zamorano, L.2
Juan, C.3
Perez, J.L.4
Ge, Y.5
Oliver, A.6
-
14
-
-
0036498656
-
Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?
-
Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002; 34(5): 634-640.
-
(2002)
Clin Infect Dis
, vol.34
, Issue.5
, pp. 634-640
-
-
Livermore, D.M.1
-
15
-
-
77955779224
-
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
-
Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10(4): 441-451.
-
(2010)
Expert Rev Pharmacoecon Outcomes Res
, vol.10
, Issue.4
, pp. 441-451
-
-
Hirsch, E.B.1
Tam, V.H.2
-
16
-
-
84945139301
-
Infections caused by resistant Gram-negative bacteria: Epidemiology and management
-
Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015; 35(10): 949-962.
-
(2015)
Pharmacotherapy
, vol.35
, Issue.10
, pp. 949-962
-
-
Kaye, K.S.1
Pogue, J.M.2
-
17
-
-
84896453665
-
Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae
-
Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014; 69(4): 871-880.
-
(2014)
J Antimicrob Chemother
, vol.69
, Issue.4
, pp. 871-880
-
-
Nguyen, H.M.1
Shier, K.L.2
Graber, C.J.3
-
18
-
-
84919640961
-
The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli
-
Park SH, Choi SM, Chang YK, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014; 69(10): 2848-2856.
-
(2014)
J Antimicrob Chemother
, vol.69
, Issue.10
, pp. 2848-2856
-
-
Park, S.H.1
Choi, S.M.2
Chang, Y.K.3
-
19
-
-
84555204766
-
Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts
-
Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012; 54(2): 167-174.
-
(2012)
Clin Infect Dis
, vol.54
, Issue.2
, pp. 167-174
-
-
Rodriguez-Bano, J.1
Navarro, M.D.2
Retamar, P.3
Picon, E.4
Pascual, A.5
-
20
-
-
84873622347
-
Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae
-
Hirsch EB, Guo B, Chang KT, et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis. 2013; 207(5): 786-793.
-
(2013)
J Infect Dis
, vol.207
, Issue.5
, pp. 786-793
-
-
Hirsch, E.B.1
Guo, B.2
Chang, K.T.3
-
21
-
-
77953552925
-
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection
-
Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010; 65(6): 1119-1125.
-
(2010)
J Antimicrob Chemother
, vol.65
, Issue.6
, pp. 1119-1125
-
-
Hirsch, E.B.1
Tam, V.H.2
-
22
-
-
84872498847
-
Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes
-
van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75(2): 115-120.
-
(2013)
Diagn Microbiol Infect Dis
, vol.75
, Issue.2
, pp. 115-120
-
-
van Duin, D.1
Kaye, K.S.2
Neuner, E.A.3
Bonomo, R.A.4
-
23
-
-
84939486487
-
The beta-lactams strike back: Ceftazidime-avibactam
-
Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015; 35(8): 755-770.
-
(2015)
Pharmacotherapy
, vol.35
, Issue.8
, pp. 755-770
-
-
Zasowski, E.J.1
Rybak, J.M.2
Rybak, M.J.3
-
24
-
-
84908582598
-
Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin
-
Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014; 58(11): 6946-6948.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.11
, pp. 6946-6948
-
-
Phe, K.1
Johnson, M.L.2
Palmer, H.R.3
Tam, V.H.4
-
25
-
-
84898606478
-
In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy
-
Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014; 58(5): 2740-2746.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.5
, pp. 2740-2746
-
-
Phe, K.1
Lee, Y.2
McDaneld, P.M.3
-
26
-
-
84969942703
-
-
[webpage on the Internet]. from: Accessed February 26, 2016
-
Merck & Co., Inc. [webpage on the Internet]. Zerbaxa Prescribing Information. Available from: http: //www.zerbaxa.com/pdf/PrescribingInformation.pdf. Accessed February 26, 2016.
-
Zerbaxa Prescribing Information
-
-
-
27
-
-
84937515119
-
Ceftolozane/tazobactam: A novel cephalosporin/beta-lactamase inhibitor combination
-
Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination. Pharmacotherapy. 2015; 35(7): 701-715.
-
(2015)
Pharmacotherapy
, vol.35
, Issue.7
, pp. 701-715
-
-
Cho, J.C.1
Fiorenza, M.A.2
Estrada, S.J.3
-
28
-
-
84455169919
-
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms
-
Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2012; 56(1): 544-549.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.1
, pp. 544-549
-
-
Bulik, C.C.1
Tessier, P.R.2
Keel, R.A.3
Sutherland, C.A.4
Nicolau, D.P.5
-
29
-
-
84875175772
-
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice
-
Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 57(4): 1577-1582.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, Issue.4
, pp. 1577-1582
-
-
Craig, W.A.1
Andes, D.R.2
-
30
-
-
77956123209
-
Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa
-
Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(9): 3933-3937.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.9
, pp. 3933-3937
-
-
Moya, B.1
Zamorano, L.2
Juan, C.3
Ge, Y.4
Oliver, A.5
-
31
-
-
79955536362
-
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
-
Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011; 55(5): 2390-2394.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, Issue.5
, pp. 2390-2394
-
-
Sader, H.S.1
Rhomberg, P.R.2
Farrell, D.J.3
Jones, R.N.4
-
33
-
-
84887449664
-
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012)
-
Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother. 2013; 57(12): 6305-6310.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, Issue.12
, pp. 6305-6310
-
-
Farrell, D.J.1
Flamm, R.K.2
Sader, H.S.3
Jones, R.N.4
-
34
-
-
84893465570
-
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates
-
Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014; 58(2): 1218-1223.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.2
, pp. 1218-1223
-
-
Snydman, D.R.1
McDermott, L.A.2
Jacobus, N.V.3
-
35
-
-
77955378731
-
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions
-
Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010; 54(8): 3427-3431.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.8
, pp. 3427-3431
-
-
Ge, Y.1
Whitehouse, M.J.2
Friedland, I.3
Talbot, G.H.4
-
36
-
-
84861121314
-
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses
-
Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56(6): 3086-3091.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.6
, pp. 3086-3091
-
-
Miller, B.1
Hershberger, E.2
Benziger, D.3
Trinh, M.4
Friedland, I.5
-
37
-
-
84896914754
-
Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam
-
Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014; 58(4): 2249-2255.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.4
, pp. 2249-2255
-
-
Wooley, M.1
Miller, B.2
Krishna, G.3
Hershberger, E.4
Chandorkar, G.5
-
38
-
-
84957928059
-
Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection
-
MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE. Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2015; 60(1): 515-521.
-
(2015)
Antimicrob Agents Chemother
, vol.60
, Issue.1
, pp. 515-521
-
-
MacGowan, A.P.1
Noel, A.R.2
Tomaselli, S.G.3
Nicholls, D.4
Bowker, K.E.5
-
40
-
-
84959868380
-
Noninferiority doesn’t mean not inferior
-
Spellberg B, Brass EP. Noninferiority doesn’t mean not inferior. Clin Infect Dis. 2016; 62(4): 525-526.
-
(2016)
Clin Infect Dis
, vol.62
, Issue.4
, pp. 525-526
-
-
Spellberg, B.1
Brass, E.P.2
-
43
-
-
84954153001
-
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
-
Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016; 56(1): 56-66.
-
(2016)
J Clin Pharmacol
, vol.56
, Issue.1
, pp. 56-66
-
-
Xiao, A.J.1
Miller, B.W.2
Huntington, J.A.3
Nicolau, D.P.4
-
44
-
-
84906085321
-
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections
-
Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58(9): 5350-5357.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.9
, pp. 5350-5357
-
-
Lucasti, C.1
Hershberger, E.2
Miller, B.3
-
45
-
-
84929832591
-
Trial of short-course antimicrobial therapy for intraabdominal infection
-
Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015; 372(21): 1996-2005.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 1996-2005
-
-
Sawyer, R.G.1
Claridge, J.A.2
Nathens, A.B.3
-
46
-
-
84964045305
-
Ceftolozane-tazobactam: A new-generation cephalosporin
-
Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm. 2015; 72(24): 2135-2146.
-
(2015)
Am J Health Syst Pharm
, vol.72
, Issue.24
, pp. 2135-2146
-
-
Cluck, D.1
Lewis, P.2
Stayer, B.3
Spivey, J.4
Moorman, J.5
-
47
-
-
84878278251
-
10 x ‘20 progress-development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America
-
Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 x ‘20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(12): 1685-1694.
-
(2013)
Clin Infect Dis
, vol.56
, Issue.12
, pp. 1685-1694
-
-
Boucher, H.W.1
Talbot, G.H.2
Benjamin, D.K.3
-
48
-
-
57749107808
-
Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America
-
Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1-12.
-
(2009)
Clin Infect Dis
, vol.48
, Issue.1
, pp. 1-12
-
-
Boucher, H.W.1
Talbot, G.H.2
Bradley, J.S.3
|